Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Harvard Bioscience, Inc.

Stage 2 · Advancing · week 11

As of Oct 22, 2026, Harvard Bioscience is in Stage 2, the uptrend phase, now in week 11 (since Aug 6, 2026). It closed at $8.34, 2.6% below its 52-week high and above its 200-day average, which is rising.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. More about the company

$8.34
-1.77% today
$38.0M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 18 in Medical Instruments & Supplies · #1 of 272 in Health Care

Is HBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 70w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 8w → S4 8w → S1 12w → S4 70w → S1 9w → S4 10w → S1 3w → S2 9w → S3 8w → S4 2w → S3 1w → S2 13w → S3 2w → S2 11w current
Total tracked: 166 weeks across 14 stage runs.

HBIO among Medical Instruments & Supplies3rd of 51 by relative strength

All 51 →
Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#StockStageRS1M
1PLSEStage 2 · wk 3498+1.3%
2PDEXStage 2 · wk 3697−13.3%
3HBIOStage 2 · wk 1195+3.6%
4ATRCStage 2 · wk 1089−1.1%
5WSTStage 2 · wk 2482+4.8%
6BDXStage 2 · wk 1181+9.8%
7ICUIStage 3 · wk 181+3.1%
8OSURStage 3 · wk 875−4.8%
vs 52W High
-2.6%
$4.00 lo$8.56 hi
2.6% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 11
1w13w26w
Week 11, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
31.0%
200 DMA: $6.37 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.23x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+3.6%
3M
+39.0%
6M
+23.0%
YTD
+28.3%
1Y
+103.4%
Scan Membership
Breakout Watch
Latest: 2023-03-30
4 appearances in last 60 days. First seen: 2020-01-07.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 11 · Vol 0.23x
2026-10-21S2
Wk 11 · Vol 0.56x
2026-10-20S2
Wk 11 · Vol 1.18x
2026-10-19S2
Wk 11 · Vol 0.63x
2026-10-16S2
Wk 11 · Vol 1.02x
2026-10-15S2
Wk 10 · Vol 0.84x
2026-10-14S2
Wk 10 · Vol 0.59x
2026-10-13S2
Wk 10 · Vol 0.33x
2026-10-12S2
Wk 10 · Vol 0.44x
2026-10-09S2
Wk 10 · Vol 0.62x
2026-10-08S2
Wk 9 · Vol 0.92x
2026-10-07S2
Wk 9 · Vol 0.42x
Moving averages & range
50 DMA
$7.93
200 DMA
$6.37
52W High
$8.56
52W Low
$4.00
5D Low
$8.09
Resistance levels (recent highs)
20d High
$8.56
60d High
$8.56
120d High
$8.56
250d High
$8.56
Next resistance
+2.6%
to 20d High
ROE
-89.9%
Profit margin -11.9%
Dividend Yield
0.00%
P/B 5.1

Harvard Bioscience: quick answers

What stage is Harvard Bioscience in?

As of Oct 22, 2026, Harvard Bioscience (HBIO) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 6, 2026 and is in week 11. What the four stages mean

Is Harvard Bioscience in an uptrend?

Yes. Harvard Bioscience is in a Stage 2 uptrend. It trades 31.0% above its 200-day average, which is rising.

How far is Harvard Bioscience from its 52-week high?

Harvard Bioscience closed at $8.34 on Oct 22, 2026, 2.6% below its 52-week high of $8.56. Its 52-week low is $4.00.

How has Harvard Bioscience performed over the past year?

As of Oct 22, 2026, Harvard Bioscience is up 103.4% over the past year and up 28.3% so far in 2026.

Which sector and industry is Harvard Bioscience in?

Harvard Bioscience is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.